Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Non-Current Assets (2021 - 2025)

Historic Non-Current Assets for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $20.7 million.

  • Lyra Therapeutics' Non-Current Assets fell 1489.8% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.9 million, marking a year-over-year decrease of 3688.58%. This contributed to the annual value of $23.3 million for FY2024, which is 3826.99% down from last year.
  • According to the latest figures from Q3 2025, Lyra Therapeutics' Non-Current Assets is $20.7 million, which was down 1489.8% from $21.5 million recorded in Q2 2025.
  • Lyra Therapeutics' 5-year Non-Current Assets high stood at $52.1 million for Q1 2024, and its period low was $5.6 million during Q1 2021.
  • For the 5-year period, Lyra Therapeutics' Non-Current Assets averaged around $16.6 million, with its median value being $9.1 million (2022).
  • Per our database at Business Quant, Lyra Therapeutics' Non-Current Assets skyrocketed by 47430.81% in 2024 and then tumbled by 5697.14% in 2025.
  • Over the past 5 years, Lyra Therapeutics' Non-Current Assets (Quarter) stood at $6.9 million in 2021, then surged by 31.52% to $9.1 million in 2022, then surged by 313.38% to $37.8 million in 2023, then crashed by 38.27% to $23.3 million in 2024, then decreased by 11.28% to $20.7 million in 2025.
  • Its last three reported values are $20.7 million in Q3 2025, $21.5 million for Q2 2025, and $22.4 million during Q1 2025.